Ifeanyichukwu Ifechidere: DOAC Interference in Coagulation Tests – Are You Spotting It?
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“That ‘positive’ lupus anticoagulant result… might not be real.
And if you don’t catch it, you could be part of a misdiagnosis.
Let me talk to you — the biomedical scientist reviewing that coag screen. You run a lupus anticoagulant panel.
dRVVT ratio? – Prolonged.
APTT-based test? – Also prolonged.
‘Positive for LA,’ right?
Not so fast.
Is the patient on a DOAC?
Because here’s what many don’t realise:
Direct oral anticoagulants (DOACs) — especially factor Xa inhibitors and direct thrombin inhibitors — can significantly interfere with phospholipid-dependent assays.
And the result? – False positives in lupus anticoagulant testing
I’ve seen it happen:
- Patients labelled as having antiphospholipid syndrome
- Unnecessary long-term anticoagulation decisions
- Clinical confusion…
All based on a misleading lab result
Here’s what should trigger your suspicion:
- Unexpected LA positivity with no clinical history
- Prolonged dRVVT and APTT in a patient on apixaban, rivaroxaban, or dabigatran
- Inconsistent confirmatory testing patterns
Because DOACs can:
- Prolong screening assays
- Affect confirmatory steps
- Mimic inhibitor patterns
And suddenly, your ‘LA positive’ isn’t a lupus anticoagulant at all…
It’s drug interference.
So before you validate that result, ask:
- ‘Do I know the anticoagulation status of this patient?’
- ‘Should this test have been performed while on a DOAC?’
- – ‘Do we need DOAC-neutralisation or alternative strategies?’
Because in coagulation…
Context isn’t optional — it’s everything.
This is the level of thinking that separates running tests from truly understanding them.
If you want to get better at spotting interferences, interpreting complex results, and protecting patients from misleading data…
I break it down with real case studies Simple, practical interpretation frameworks. No jargon. Just clarity. Because not every abnormal result is pathology. Sometimes… it’s the test being fooled.”

Other posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
May 12, 2026, 14:46Yusra Iqbal: What Hemophilia Teaches Us About Modern Hematology
-
May 12, 2026, 14:45Seema Dawood: Platelet Production and the Role of Thrombopoietin
-
May 12, 2026, 14:43Abdou Salam Poutougnigni: Honored to Represent Fondation Pierre Fabre at the Africa CDC Sickle Cell Disease Validation Conference
-
May 12, 2026, 14:42Suleiman Malhi at Sundas Foundation with Blood Donation Society on the occasion of World Thalassemia Day
-
May 12, 2026, 14:39Neil Blumberg: Why Washed Red Cell and Platelet Transfusions Deserve More Attention
-
May 12, 2026, 14:34Wajeeha Rashid: Research Poster Award at MedExpo 2.0
-
May 12, 2026, 14:27Intezar Mehdi: When Frequent Nosebleeds Are Not Just a Minor Issue
-
May 12, 2026, 14:22Understanding the Human Side of Hemophilia Gene Therapy – ISTH
-
May 12, 2026, 14:01Moses Wasswa: Tackling Sickle Cell Disease in Uganda